Annual CFO
$4.59 B
-$420.90 M-8.39%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual cash flow from operations is currently $4.59 billion, with the most recent change of -$420.90 million (-8.39%) on 31 December 2023. During the last 3 years, it has risen by +$1.98 billion (+75.47%). REGN annual CFO is now -35.12% below its all-time high of $7.08 billion, reached on 31 December 2021.REGN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$1.29 B
+$937.20 M+264.75%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly cash flow from operations is currently $1.29 billion, with the most recent change of +$937.20 million (+264.75%) on 30 September 2024. Over the past year, it has increased by +$176.90 million (+15.88%). REGN quarterly CFO is now -62.17% below its all-time high of $3.41 billion, reached on 30 September 2021.REGN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$4.25 B
+$176.90 M+4.35%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM cash flow from operations is currently $4.25 billion, with the most recent change of +$176.90 million (+4.35%) on 30 September 2024. Over the past year, it has dropped by -$976.80 million (-18.70%). REGN TTM CFO is now -50.12% below its all-time high of $8.51 billion, reached on 31 March 2022.REGN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -8.4% | +15.9% | -18.7% |
| 3 y3 years | +75.5% | -62.2% | -28.5% |
| 5 y5 years | +109.3% | +131.7% | +79.1% |
REGN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -35.1% | +75.5% | -62.2% | +264.8% | -50.1% | +4.3% |
| 5 y | 5 years | -35.1% | +109.3% | -62.2% | +607.8% | -50.1% | +95.3% |
| alltime | all time | -35.1% | +3342.5% | -62.2% | +607.8% | -50.1% | +1718.2% |
Regeneron Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.29 B(+264.7%) | $4.25 B(+4.3%) |
| June 2024 | - | $354.00 M(-76.6%) | $4.07 B(-14.1%) |
| Mar 2024 | - | $1.51 B(+38.8%) | $4.74 B(+3.2%) |
| Dec 2023 | $4.59 B(-8.4%) | $1.09 B(-2.2%) | $4.59 B(-12.1%) |
| Sept 2023 | - | $1.11 B(+9.0%) | $5.22 B(+10.2%) |
| June 2023 | - | $1.02 B(-25.2%) | $4.74 B(+10.7%) |
| Mar 2023 | - | $1.37 B(-20.5%) | $4.28 B(-14.6%) |
| Dec 2022 | $5.01 B(-29.2%) | $1.72 B(+173.5%) | $5.01 B(-11.5%) |
| Sept 2022 | - | $628.90 M(+11.4%) | $5.67 B(-32.9%) |
| June 2022 | - | $564.40 M(-73.1%) | $8.45 B(-0.7%) |
| Mar 2022 | - | $2.10 B(-11.4%) | $8.51 B(+20.2%) |
| Dec 2021 | $7.08 B(+170.5%) | $2.37 B(-30.5%) | $7.08 B(+19.2%) |
| Sept 2021 | - | $3.41 B(+444.7%) | $5.94 B(+161.4%) |
| June 2021 | - | $626.70 M(-6.3%) | $2.27 B(-12.2%) |
| Mar 2021 | - | $668.50 M(-45.7%) | $2.59 B(-1.1%) |
| Dec 2020 | $2.62 B(+7.7%) | $1.23 B(-584.1%) | $2.62 B(+20.4%) |
| Sept 2020 | - | -$254.30 M(-127.0%) | $2.17 B(-27.2%) |
| June 2020 | - | $943.40 M(+35.2%) | $2.99 B(+33.8%) |
| Mar 2020 | - | $698.00 M(-11.4%) | $2.23 B(-8.2%) |
| Dec 2019 | $2.43 B(+10.7%) | $787.40 M(+41.3%) | $2.43 B(+2.5%) |
| Sept 2019 | - | $557.30 M(+196.0%) | $2.37 B(+4.6%) |
| June 2019 | - | $188.30 M(-79.0%) | $2.27 B(-8.3%) |
| Mar 2019 | - | $897.00 M(+23.1%) | $2.47 B(+12.7%) |
| Dec 2018 | $2.20 B(+67.9%) | $728.80 M(+60.9%) | $2.20 B(+8.0%) |
| Sept 2018 | - | $452.90 M(+14.8%) | $2.03 B(+1.9%) |
| June 2018 | - | $394.60 M(-36.2%) | $2.00 B(+27.1%) |
| Mar 2018 | - | $618.80 M(+9.1%) | $1.57 B(+20.1%) |
| Dec 2017 | $1.31 B(-12.0%) | $566.94 M(+36.7%) | $1.31 B(+15.6%) |
| Sept 2017 | - | $414.83 M(-1457.0%) | $1.13 B(-17.3%) |
| June 2017 | - | -$30.57 M(-108.6%) | $1.37 B(-23.9%) |
| Mar 2017 | - | $355.90 M(-8.8%) | $1.80 B(+20.9%) |
| Dec 2016 | $1.49 B(+11.7%) | $390.38 M(-40.0%) | $1.49 B(+7.9%) |
| Sept 2016 | - | $651.03 M(+63.0%) | $1.38 B(-14.9%) |
| June 2016 | - | $399.50 M(+788.0%) | $1.62 B(+9.6%) |
| Mar 2016 | - | $44.99 M(-84.0%) | $1.48 B(+11.0%) |
| Dec 2015 | $1.33 B(+76.9%) | $281.82 M(-68.4%) | $1.33 B(+6.7%) |
| Sept 2015 | - | $892.85 M(+246.3%) | $1.25 B(+140.5%) |
| June 2015 | - | $257.83 M(-353.5%) | $518.60 M(-13.2%) |
| Mar 2015 | - | -$101.73 M(-151.3%) | $597.18 M(-20.6%) |
| Dec 2014 | $752.43 M(+27.8%) | $198.18 M(+20.6%) | $752.43 M(-10.0%) |
| Sept 2014 | - | $164.32 M(-51.2%) | $835.99 M(+9.4%) |
| June 2014 | - | $336.41 M(+528.5%) | $764.12 M(+37.5%) |
| Mar 2014 | - | $53.53 M(-81.0%) | $555.88 M(-5.6%) |
| Dec 2013 | $588.60 M(-888.8%) | $281.73 M(+204.7%) | $588.60 M(+47.1%) |
| Sept 2013 | - | $92.45 M(-27.9%) | $400.05 M(+31.1%) |
| June 2013 | - | $128.16 M(+48.6%) | $305.21 M(+209.3%) |
| Mar 2013 | - | $86.25 M(-7.4%) | $98.67 M(-232.2%) |
| Dec 2012 | -$74.61 M(-47.3%) | $93.19 M(-4012.0%) | -$74.61 M(-65.8%) |
| Sept 2012 | - | -$2.38 M(-97.0%) | -$218.12 M(-16.9%) |
| June 2012 | - | -$78.38 M(-10.0%) | -$262.47 M(+20.3%) |
| Mar 2012 | - | -$87.04 M(+73.0%) | -$218.14 M(+54.0%) |
| Dec 2011 | -$141.68 M(-242.8%) | -$50.32 M(+7.7%) | -$141.68 M(+7.2%) |
| Sept 2011 | - | -$46.73 M(+37.3%) | -$132.22 M(-273.9%) |
| June 2011 | - | -$34.05 M(+221.8%) | $76.02 M(-22.6%) |
| Mar 2011 | - | -$10.58 M(-74.1%) | $98.22 M(-1.0%) |
| Dec 2010 | $99.22 M(-237.4%) | -$40.85 M(-125.3%) | $99.22 M(+5.9%) |
| Sept 2010 | - | $161.50 M(-1462.9%) | $93.67 M(-220.6%) |
| June 2010 | - | -$11.85 M(+23.7%) | -$77.65 M(+16.9%) |
| Mar 2010 | - | -$9.58 M(-79.4%) | -$66.43 M(-8.0%) |
| Dec 2009 | -$72.23 M(-18.9%) | -$46.40 M(+372.4%) | -$72.23 M(+17.1%) |
| Sept 2009 | - | -$9.82 M(+1476.6%) | -$61.67 M(-34.0%) |
| June 2009 | - | -$623.00 K(-95.9%) | -$93.39 M(+7.9%) |
| Mar 2009 | - | -$15.38 M(-57.1%) | -$86.57 M(-2.8%) |
| Dec 2008 | -$89.09 M | -$35.84 M(-13.7%) | -$89.09 M(+3567.6%) |
| Sept 2008 | - | -$41.55 M(-770.4%) | -$2.43 M(-108.5%) |
| June 2008 | - | $6.20 M(-134.6%) | $28.42 M(+51.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$17.90 M(-135.2%) | $18.71 M(-31.6%) |
| Dec 2007 | $27.37 M(+18.6%) | $50.82 M(-574.9%) | $27.37 M(-8.3%) |
| Sept 2007 | - | -$10.70 M(+205.1%) | $29.86 M(+16.1%) |
| June 2007 | - | -$3.51 M(-62.0%) | $25.73 M(+200.6%) |
| Mar 2007 | - | -$9.24 M(-117.3%) | $8.56 M(-62.9%) |
| Dec 2006 | $23.07 M(-176.2%) | $53.30 M(-459.4%) | $23.07 M(-146.1%) |
| Sept 2006 | - | -$14.83 M(-28.3%) | -$50.08 M(-0.3%) |
| June 2006 | - | -$20.68 M(-491.7%) | -$50.24 M(-13.6%) |
| Mar 2006 | - | $5.28 M(-126.6%) | -$58.15 M(+91.9%) |
| Dec 2005 | -$30.30 M(+79.2%) | -$19.85 M(+32.3%) | -$30.30 M(+33.8%) |
| Sept 2005 | - | -$15.00 M(-47.5%) | -$22.65 M(+101.6%) |
| June 2005 | - | -$28.58 M(-186.3%) | -$11.24 M(-132.3%) |
| Mar 2005 | - | $33.13 M(-371.6%) | $34.80 M(-305.8%) |
| Dec 2004 | -$16.91 M(+175.7%) | -$12.20 M(+240.2%) | -$16.91 M(-49.0%) |
| Sept 2004 | - | -$3.59 M(-120.5%) | -$33.14 M(-202.7%) |
| June 2004 | - | $17.46 M(-194.0%) | $32.26 M(-224.5%) |
| Mar 2004 | - | -$18.58 M(-34.6%) | -$25.91 M(+322.4%) |
| Dec 2003 | -$6.13 M(-94.5%) | -$28.43 M(-146.0%) | -$6.13 M(-29.7%) |
| Sept 2003 | - | $61.81 M(-251.8%) | -$8.73 M(-90.8%) |
| June 2003 | - | -$40.71 M(-3512.2%) | -$94.39 M(+13.4%) |
| Mar 2003 | - | $1.19 M(-103.8%) | -$83.28 M(-24.7%) |
| Dec 2002 | -$110.52 M(+92.8%) | -$31.03 M(+30.1%) | -$110.52 M(+13.8%) |
| Sept 2002 | - | -$23.85 M(-19.4%) | -$97.15 M(+2.1%) |
| June 2002 | - | -$29.59 M(+13.6%) | -$95.19 M(+27.0%) |
| Mar 2002 | - | -$26.05 M(+47.6%) | -$74.98 M(+30.8%) |
| Dec 2001 | -$57.32 M(+105.4%) | -$17.65 M(-19.4%) | -$57.32 M(+32.0%) |
| Sept 2001 | - | -$21.89 M(+133.4%) | -$43.44 M(+70.1%) |
| June 2001 | - | -$9.38 M(+11.7%) | -$25.53 M(+29.5%) |
| Mar 2001 | - | -$8.40 M(+122.7%) | -$19.72 M(-29.3%) |
| Dec 2000 | -$27.91 M(+106.7%) | -$3.77 M(-5.4%) | -$27.91 M(+65.7%) |
| Sept 2000 | - | -$3.99 M(+11.7%) | -$16.84 M(-18.1%) |
| June 2000 | - | -$3.57 M(-78.5%) | -$20.55 M(-5.2%) |
| Mar 2000 | - | -$16.59 M(-327.2%) | -$21.69 M(+60.6%) |
| Dec 1999 | -$13.50 M(+32.4%) | $7.30 M(-194.8%) | -$13.50 M(-49.1%) |
| Sept 1999 | - | -$7.70 M(+63.8%) | -$26.50 M(+81.5%) |
| June 1999 | - | -$4.70 M(-44.0%) | -$14.60 M(+1.4%) |
| Mar 1999 | - | -$8.40 M(+47.4%) | -$14.40 M(+41.2%) |
| Dec 1998 | -$10.20 M(+67.2%) | -$5.70 M(-235.7%) | -$10.20 M(+628.6%) |
| Sept 1998 | - | $4.20 M(-193.3%) | -$1.40 M(-80.8%) |
| June 1998 | - | -$4.50 M(+7.1%) | -$7.30 M(+5.8%) |
| Mar 1998 | - | -$4.20 M(-235.5%) | -$6.90 M(+13.1%) |
| Dec 1997 | -$6.10 M(-70.0%) | $3.10 M(-282.4%) | -$6.10 M(-34.4%) |
| Sept 1997 | - | -$1.70 M(-58.5%) | -$9.30 M(-36.3%) |
| June 1997 | - | -$4.10 M(+20.6%) | -$14.60 M(-11.0%) |
| Mar 1997 | - | -$3.40 M(+3300.0%) | -$16.40 M(-19.2%) |
| Dec 1996 | -$20.30 M(+11.5%) | -$100.00 K(-98.6%) | -$20.30 M(+12.2%) |
| Sept 1996 | - | -$7.00 M(+18.6%) | -$18.10 M(-19.2%) |
| June 1996 | - | -$5.90 M(-19.2%) | -$22.40 M(+18.5%) |
| Mar 1996 | - | -$7.30 M(-447.6%) | -$18.90 M(+3.8%) |
| Dec 1995 | -$18.20 M(-11.2%) | $2.10 M(-118.6%) | -$18.20 M(-42.6%) |
| Sept 1995 | - | -$11.30 M(+370.8%) | -$31.70 M(+20.5%) |
| June 1995 | - | -$2.40 M(-63.6%) | -$26.30 M(+45.3%) |
| Mar 1995 | - | -$6.60 M(-42.1%) | -$18.10 M(-11.7%) |
| Dec 1994 | -$20.50 M(-31.9%) | -$11.40 M(+93.2%) | -$20.50 M(+13.3%) |
| Sept 1994 | - | -$5.90 M(-201.7%) | -$18.10 M(-0.5%) |
| June 1994 | - | $5.80 M(-164.4%) | -$18.20 M(-42.8%) |
| Mar 1994 | - | -$9.00 M(0.0%) | -$31.80 M(+5.6%) |
| Dec 1993 | -$30.10 M(+75.0%) | -$9.00 M(+50.0%) | -$30.10 M(+11.1%) |
| Sept 1993 | - | -$6.00 M(-23.1%) | -$27.10 M(+8.8%) |
| June 1993 | - | -$7.80 M(+6.8%) | -$24.90 M(+16.9%) |
| Mar 1993 | - | -$7.30 M(+21.7%) | -$21.30 M(+23.8%) |
| Dec 1992 | -$17.20 M(+152.9%) | -$6.00 M(+57.9%) | -$17.20 M(+53.6%) |
| Sept 1992 | - | -$3.80 M(-9.5%) | -$11.20 M(+51.4%) |
| June 1992 | - | -$4.20 M(+31.3%) | -$7.40 M(+131.3%) |
| Mar 1992 | - | -$3.20 M | -$3.20 M |
| Dec 1991 | -$6.80 M | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual CFO year-on-year change?
- What is Regeneron Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly CFO year-on-year change?
- What is Regeneron Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM CFO year-on-year change?
What is Regeneron Pharmaceuticals annual cash flow from operations?
The current annual CFO of REGN is $4.59 B
What is the all time high annual CFO for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual cash flow from operations is $7.08 B
What is Regeneron Pharmaceuticals annual CFO year-on-year change?
Over the past year, REGN annual cash flow from operations has changed by -$420.90 M (-8.39%)
What is Regeneron Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of REGN is $1.29 B
What is the all time high quarterly CFO for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly cash flow from operations is $3.41 B
What is Regeneron Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, REGN quarterly cash flow from operations has changed by +$176.90 M (+15.88%)
What is Regeneron Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of REGN is $4.25 B
What is the all time high TTM CFO for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM cash flow from operations is $8.51 B
What is Regeneron Pharmaceuticals TTM CFO year-on-year change?
Over the past year, REGN TTM cash flow from operations has changed by -$976.80 M (-18.70%)